

CASE REPORT

COVID-19 and Kawasaki Disease: Novel Virus and Novel Case

Veena G. Jones, MD,^{a,b,*} Marcos Mills, MD,^{c,d,*} Dominique Suarez, MD,^a Catherine A. Hogan, MD,^e Debra Yeh, MD,^d J. Bradley Segal, MD,^d Elizabeth L. Nguyen, MD,^d Gabrielle R. Barsh, MD, PhD, MD,^d Shiraz Maskatia, MD,^{c,d} Roshni Mathew, MD^{d,f}

ABSTRACT

In the midst of the coronavirus disease 2019 (COVID-19) pandemic, we are seeing widespread disease burden affecting patients of all ages across the globe. However, much remains to be understood as clinicians, epidemiologists, and researchers alike are working to describe and characterize the disease process while caring for patients at the frontlines. We describe the case of a 6-month-old infant admitted and diagnosed with classic Kawasaki disease, who also screened positive for COVID-19 in the setting of fever and minimal respiratory symptoms. The patient was treated per treatment guidelines, with intravenous immunoglobulin and high-dose aspirin, and subsequently defervesced with resolution of her clinical symptoms. The patient's initial echocardiogram was normal, and she was discharged within 48 hours of completion of her intravenous immunoglobulin infusion, with instruction to quarantine at home for 14 days from the date of her positive test results for COVID-19. Further study of the clinical presentation of pediatric COVID-19 and the potential association with Kawasaki disease is warranted, as are the indications for COVID-19 testing in the febrile infant.

www.hospitalpediatrics.org

DOI: <https://doi.org/10.1542/hpeds.2020-0123>

Copyright © 2020 by the American Academy of Pediatrics

Address correspondence to Veena G. Jones, MD, Division of Pediatric Hospital Medicine, Palo Alto Foundation Medical Group, Palo Alto Medical Foundation, 795 El Camino Real, Palo Alto, CA 94304. E-mail: jonesvg@sutterhealth.org

HOSPITAL PEDIATRICS (ISSN Numbers: Print, 2154-1663; Online, 2154-1671).

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: No external funding.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

*Contributed equally as co-first authors.

Dr Jones provided direct care to the patient in this report, conceptualized and outlined the manuscript, reviewed existing literature, and drafted the initial manuscript; Dr Mills reviewed existing literature and drafted the initial manuscript; Dr Suarez provided direct care to the patient in this report and contributed to the drafting of the initial manuscript; Dr Hogan contributed to the drafting of the initial manuscript; Drs Yeh, Segal, Nguyen, and Barsh provided direct care to the patient in this report; Dr Maskatia is providing ongoing care to the patient; Dr Mathew conceptualized and outlined the manuscript; and all authors reviewed and revised the manuscript, approved the final manuscript as submitted, and agree to be accountable for all aspects of the work.

^aDivision of Pediatric Hospital Medicine, Palo Alto Foundation Medical Group and ^bPalo Alto Medical Foundation Research Institute, Palo Alto Medical Foundation, Sutter Health, Palo Alto, California; and ^cDivisions of Pediatric Cardiology and ^dPediatric Infectious Disease and ^eClinical Virology Laboratory, Department of Pathology and ^fDepartment of Pediatrics, Stanford Medicine, Stanford University, Stanford, California

The rapid spread of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 has led to a global pandemic, with infected individuals of all ages residing in almost every country in the world. The pediatric population appears to be affected in much smaller proportions than adults, with only 2% of cases described in patients younger than age 20.¹ In an epidemiological report, authors described 731 confirmed COVID-19 cases in the pediatric population, with >90% of patients characterized as asymptomatic, mild, or moderate cases.² The authors looked at a total of 2143 patients, 1412 of whom had suspected but unconfirmed COVID-19 infection, but there was little description of co-incidence with other clinical conditions and no cases reported of concurrent Kawasaki disease (KD).

We describe here the case of a pediatric patient diagnosed and treated for classic KD in the setting of confirmed COVID-19 infection, published with parental permission.

CASE DESCRIPTION

The patient is a 6-month-old, term, previously healthy and fully immunized girl who initially presented to pediatric urgent care with 1 day of fever, fussiness, and refusal to eat. She did not exhibit cough, congestion, or rhinorrhea. Examination revealed a fussy infant with a temperature of 38.8°C, with no focal signs of infection. Laboratory evaluation included a rapid influenza swab and a catheterized urinalysis with urine culture, all of which had negative results. She was diagnosed with a viral infection.

On day 2 of fever, she developed an erythematous, seemingly nonpruritic, blotchy rash. She re-presented to care on day 4 of fever with persistent rash. Although she remained free of cough, there was possible mild congestion. Vital signs revealed a temperature of 38.3°C, sinus tachycardia (200 beats per minute), and tachypnea with an oxygen saturation of 100%. Examination was notable for irritability, limbic sparing conjunctivitis, and dry cracked lips. There was no appreciable lymphadenopathy, and, at the time, she had

normal extremities. She had mild subcostal retractions, although she had normal breath sounds. Laboratory testing revealed a left-shifted white blood cell count with bandemia, normocytic anemia, normal platelets, markedly elevated C-reactive protein of 13.3 mg/dL, and erythrocyte sedimentation rate of 118. She had hyponatremia (sodium at 133) and hypoalbuminemia (albumin at 2.8), with otherwise normal chemistries, including liver function tests. Results from respiratory pathogen testing by reverse transcription polymerase chain reaction (RT-PCR) test and blood culture were negative. A chest radiograph revealed a faint opacity in the left midlung zone. Throughout this period of illness, she had no sick contacts. Her 9-year-old sibling had upper respiratory symptoms 3 weeks before. The family had self-isolated because of the COVID-19 pandemic for the week before, without leaving home for school or work. There was no history of recent travel.

The patient was referred for admission for KD evaluation. Given her fever, possible mild congestion, and chest radiograph findings, she was sent to the emergency department for COVID-19 testing before admission to the pediatric floor. On arrival, the patient was on day 5 of fever and had limbic sparing conjunctivitis (Fig 1); prominent tongue papilla; a blanching, polymorphous, maculopapular rash (Fig 2); and swelling of



FIGURE 1 Bulbar conjunctival injection. The image is shared with parental permission.

the hands (Fig 3) and lower extremities (thus meeting classic criteria for KD). She was treated with a single dose of 2 g/kg intravenous immunoglobulin and high-dose acetylsalicylic acid (20 mg/kg 4 times daily), according to treatment guidelines.³ Her last elevated temperature was 38.3°C, just after completing intravenous immunoglobulin. An echocardiogram was normal without any evidence of coronary dilation or aneurysm, no pericardial effusion, and with normal valvar and ventricular function.

The evening before discharge, RT-PCR testing for COVID-19 resulted positive from the Stanford Health Care Clinical Virology Laboratory. The public health department was notified, and the family was instructed to quarantine at home for 14 days from the positive test result date. She was discharged on low-dose acetylsalicylic acid (3 mg/kg daily), with plans to follow-up with pediatric cardiology for repeat echocardiographic evaluation 2 weeks after discharge, timed to occur after the mandated 14-day quarantine.

DISCUSSION

To our knowledge, this is the first described case of KD with concurrent COVID-19 infection. KD is an acute vasculitis of childhood and the leading cause of acquired heart disease in children in developed



FIGURE 2 Maculopapular rash. The image is shared with parental permission.



FIGURE 3 Upper extremity erythema and edema. The image is shared with parental permission.

countries, with 50% of cases occurring in those <2 years of age and 80% in those <5 years of age.⁴ The diagnosis of “classic” KD is considered in patients presenting with fever for 5 days together with at least 4 out of 5 clinical criteria in the absence of an alternate diagnosis.

The cause of KD remains unknown despite several decades of investigation. Some evidence suggests an infectious trigger, with winter to spring seasonality of the disease, and wavelike spread of Japanese epidemics of KD.⁴ In various studies, authors have described an association between viral respiratory infections and KD, ranging from 9% to as high as 42% of patients with KD testing positive for a respiratory viral infection in the 30 days leading up to diagnosis of KD.^{5–7} Interestingly, Turnier et al⁵ in 2015 described that 28% of positive results were attributable to rhinovirus and/or enterovirus, and 8.7% were due to parainfluenza; results for the remaining pathogens (respiratory syncytial virus, influenza, adenovirus, and human coronavirus [strains 229E, HKU1, NL63, OC43]) were each positive <5% of the time.

Although the clinical significance of our patient’s positive COVID-19 test result in the setting of her KD is not clear, her testing for COVID-19 appears accurate. The Stanford Health Care Clinical Virology Laboratory

serves pediatric and adult tertiary-care hospitals and affiliated clinics in northern California. In early January 2020, 2 multiplex RT-PCR assays were validated on the basis of a modified published protocol.⁸ These assays are used to target the envelope and RNA-dependent RNA-polymerase genes, respectively. Analytical sensitivity from nasopharyngeal swabs eluted in viral transport medium was shown to be good, with a lower limit of detection ranging between 500 and 700 copies per mL. Furthermore, analytical specificity was high, with no cross-reactivity observed in >50 tested samples with seasonal coronaviruses or other respiratory viruses. Samples revealing late cycle threshold values (cycle threshold ≥ 40) are repeated for confirmatory testing to prevent false-positive results. Although direct comparison data between this assay and the Centers for Disease Control and Prevention’s assay (which targets 2 regions of the nucleocapsid gene) have not yet been published, preliminary data suggest similar analytic performance.^{8,9}

At the time of this patient’s hospital discharge, the World Health Organization reported almost 180 000 global cases of confirmed COVID-19, with 7426 deaths.¹⁰ Despite the growing number of reported cases, there remains a knowledge gap regarding the infectious, epidemiological, and clinical features associated with COVID-19 illness, particularly in the pediatric population. To date, the most common pediatric presentation of COVID-19 is an array of signs and symptoms including completely asymptomatic to symptoms of acute upper respiratory tract infection such as fever, fatigue, cough, sore throat, rhinorrhea and congestion, and shortness of breath. In more severe cases, symptoms can include gastrointestinal symptoms and patients can progress to respiratory failure, shock, coagulation dysfunction, and renal injury.²

With regard to her COVID-19 infection, our patient’s clinical course and presentation were mild. Throughout her hospitalization, she did not have any notable respiratory symptoms, and repeat chest radiograph was not obtained. Her mother was in close

contact with the infant throughout hospitalization and has no respiratory symptoms as of 2 weeks after hospital discharge. When coronary involvement appears with KD, it typically occurs after the initial presentation. As such, recommendations for monitoring include echocardiography in 1 to 2 weeks and 4 to 6 weeks after treatment.³

As we continue to see the spread of COVID-19 and increase in cases worldwide, clinical criteria for testing for COVID-19 may be restricted to those with respiratory symptoms because of constraints such as testing availability. In pediatrics, with the clinical spectrum yet to be clearly defined, patients presenting with fever alone or primarily with other organ system involvement such as gastrointestinal symptoms may be missed if testing is restricted to those with respiratory complaints alone.

CONCLUSIONS

This case report may serve as a useful reference to other clinicians caring for pediatric patients affected by COVID-19 as understanding of the clinical presentation patterns continues to evolve. Further description of the clinical course of pediatric patients diagnosed with COVID-19 remains necessary, particularly regarding the potential association with KD.

Acknowledgments

We thank the patient and her family for their willingness to share this case and the images. We also thank all the members of the health care team who contributed to the care of the patient discussed in this case report. In particular, we thank Dr Katherine Fry (Palo Alto Medical Foundation pediatric hospitalist).

REFERENCES

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323(13):1239–1242
2. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China

- [published online ahead of print March 16, 2020]. *Pediatrics*. doi:10.1542/peds.2020-0702
3. McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association [published correction appears in *Circulation*. 2019; 140(5):e181–e184]. *Circulation*. 2017; 135(17):e927–e999
 4. Rowley AH, Shulman ST. The epidemiology and pathogenesis of Kawasaki disease. *Front Pediatr*. 2018;6:374
 5. Turnier JL, Anderson MS, Heizer HR, Jone P-N, Glodé MP, Domínguez SR. Concurrent respiratory viruses and Kawasaki disease. *Pediatrics*. 2015; 136(3). Available at: www.pediatrics.org/cgi/content/full/136/3/e609
 6. Kim JH, Yu JJ, Lee J, et al. Detection rate and clinical impact of respiratory viruses in children with Kawasaki disease. *Korean J Pediatr*. 2012;55(12):470–473
 7. Jordan-Villegas A, Chang ML, Ramilo O, Mejías A. Concomitant respiratory viral infections in children with Kawasaki disease. *Pediatr Infect Dis J*. 2010;29(8): 770–772
 8. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25(3):2000045
 9. Centers for Disease Control and Prevention. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. Available at: <https://www.fda.gov/media/134922/download>. Accessed March 20, 2020
 10. World Health Organization. Coronavirus disease 2019 (COVID-19). Situation report – 57. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200317-sitrep-57-covid-19.pdf?sfvrsn=a26922f2_2. Accessed March 17, 2020